Introduction
============

Type 2 diabetes mellitus (T2DM), a progressive disease characterized by insulin resistance and eventual insulin deficiency, is caused by a gradual decrease of insulin secretion following loss of beta-cell function ([@b86]). This pathology results in progressively increasing blood glucose levels. Typically, postprandial plasma glucose (PPG) becomes elevated first, with fasting glucose ultimately increasing as well ([@b15]). Interventional studies have established chronic high blood glucose (assessed by HbA1c) as a CVD risk factor ([@b101]; [@b19]). That elevated PPG is an independent risk factor for CVD has further been implicated from epidemiological studies ([@b21]). Diabetes is also associated with other risk factors such as hypertension, adverse lipid profiles and obesity. Even after correcting for these risk factors, CVD rates are still higher in patients with diabetes than in non-diabetic subjects, implying that hyperglycemia per se may amplify the underlying risk of CVD.

This increased risk of CVD and related problems leads to a higher risk of mortality compared with the general population. Epidemiological research conducted by the Centers for Disease Control and Prevention (CDC) ([@b12]) examined the impact of T2DM on cardiovascular events and mortality, reaching the following conclusions:

-   CVD is the leading cause of death among patients with diabetes;

-   CVD death rates are 2--4 times higher in adults with diabetes than in controls;

-   Risk for stroke is 2--4 times higher among patients with diabetes than in those without it.

The objective of this article is to provide an overview of CVD risk factors in diabetes with emphasis on the role of glycemic control, and to examine whether current therapies in T2DM have beneficial effects on markers of macrovascular disease. Using recent data from treat-to-target trials, the review will consider insulin plus oral antidiabetic drug (OAD) treatments and their effect on glycemic control and cardiovascular risk factors.

Cardiovascular (CV) risk in diabetes
====================================

Although mortality due to CVD is declining in non-diabetic populations, patients with T2DM are at a high risk of CV morbidity and mortality ([@b49]; [@b96]). Some studies have reported that almost 75% of patients with T2DM die of macrovascular events, such as acute myocardial infarction (MI) and stroke ([@b58]). In a mortality study of more than 3000 patients, 4-year survival was 92% for patients with diabetes duration ≤5 years, and 84% if diabetes duration was \>5 years ([@b6]). Most deaths were due to CVD (36% and 41% for diabetes duration ≤5 years and \>5 years, respectively) ([@b6]). A 7-year Finnish study suggested that the CV event rate for patients with diabetes *without* prior MI was as high as the event rate in patients without diabetes *with* prior MI ([@b33]).

CVDs common in T2DM include coronary artery disease, stroke, peripheral vascular disease, cardiomyopathy and congestive heart failure. Several of these pathologies are usually present in a majority of patients; therefore most patients require multiple interventions ([@b48]). At the 2007 annual meeting of the American Diabetes Association, the authors of a 3.3 million population-based study proposed that patients with T2DM should be treated with antiplatelet drugs, statins, ACE inhibitors, or angiotensin receptor blockers, because they carry the same CV risk as patients with a history of MI ([@b97]).

Although CVD accounts for a high proportion of deaths, patient awareness remains low ([@b12]), and opportunities to intervene and modify the risks are missed. The high risk of morbidity and mortality in patients with diabetes indicates that it is vital to implement timely interventions in order to minimize CV complications ([@b100]).

Factors contributing to increased CV risk in diabetes
=====================================================

Patients with T2DM usually present various factors contributing to the risk of CV problems. These include hyperglycemia and fluctuation of blood glucose, central (visceral) obesity, hypertension, lipid abnormalities, hyperinsulinemia, and endothelial dysfunction ([@b100]).

The increased risk of CV morbidity and mortality associated with diabetes has led to the concept that hyperglycemia may be one of the risk factors for CVD ([@b32]). A prospective study of CVD in patients with T2DM reported that CVD episodes at 6.3 years were related to baseline HbA1c ([@b93]). A significant increase in the risk for CV events and mortality has been reported in patients with HbA1c \>7% compared with those who had lower HbA1c values ([@b57]). The UK Prospective Diabetes Study (UKPDS) showed a more than 2-fold increase in incidence of MI over a range of HbA1c values from \<6% to ≥10%; each 1% reduction in HbA1c was associated with a reduction in risk of 21% for any diabetes endpoint and death, and 14% for MI ([@b101]) ([Figure 1](#fig1){ref-type="fig"}).

![Improvement in glycemic control reduces risks of long-term complications ([@b101]).](vhrm0403-561-01){#fig1}

PPG control also plays a significant role in overall glycemic control and becomes even more important than fasting plasma glucose (FPG) when better control (eg, HbA1c level \<8.4%) is achieved ([@b77]). Excessive postprandial hyperglycemia may also be an important independent contributor to the risk of CV complications and mortality in T2DM ([@b71]; [@b13]). Interestingly, the deterioration of glucose homeostasis in the evolution of T2DM progresses from postprandial to fasting hyperglycemia ([@b78]). The Diabetes Intervention Study showed that PPG level can be used to predict the risk of MI ([@b37]). In a more recent, 5-year prospective study, PPG was an independent CVD risk factor in patients with T2DM, particularly women ([@b11]). Thus, attaining glycemic control, and reducing CVD risk, may be difficult without adequate control of PPG levels.

Another major risk factor for developing T2DM is obesity. An estimated 80% of patients with T2DM are overweight and of that 37% are obese prior to diagnosis ([@b112]). Epidemiological studies have demonstrated a clear association between obesity and CVD ([@b60]), with visceral rather than peripheral fat being most harmful. A recent cross-sectional study of 44,042 patients with T2DM reported that 80% were overweight and 37% obese ([@b90]). Such excessive weight is associated with insulin resistance, impaired glucose homeostasis, dyslipidemia, and hypertension -- all risk factors associated with CVD.

Hypertension is also a major risk factor for such microvascular and macrovascular complications as retinopathy, nephropathy, stroke, and MI. It is estimated that the prevalence of hypertension in T2DM ranges from 20% to 60% ([@b2]), more than twice that seen in controls. In the Multiple Risk Factor Intervention Trial (MRFIT), mortality risk increased with increasing blood pressure, and the absolute level of risk in patients with diabetes was at least 3 times higher than that in controls ([@b98]). In another study of patients with T2DM, hypertension and HbA1c at baseline were related to CVD episodes after 6 years ([@b93]). The UKPDS demonstrated that blood pressure control achieved with lifestyle modification and pharmacotherapy can result in risk reductions of 24% in diabetes-related endpoints, 32% in diabetes-related deaths, and 44% in stroke ([@b106]).

Another complication associated with diabetes is a chronic, low-level inflammatory state, possibly caused by oxidative stress or by glycosylation of proteins that activate macrophages. Elevated levels of C-reactive protein -- a marker of subclinical inflammation -- present in patients with T2DM, especially among older age groups ([@b46]), have been identified as a predictor of first MI and CVD ([@b92]). In case of impaired metabolic state, postprandial hyperglycemia increases the magnitude and duration of systemic inflammatory responses, possibly promoting the development of T2DM and CVD ([@b51]). Elevated C-reactive protein levels have also been reported in patients with type 1 diabetes (T1DM) without macrovascular disease, suggesting that inflammation precedes atherosclerosis ([@b95]).

Lipid abnormalities such as elevated levels of triglycerides (TG), small dense LDL cholesterol and decreased levels of HDL cholesterol have been consistently reported in diabetes, and these abnormalities dramatically increase the risk of macrovascular disease ([@b89]). In the Diabetes Control and Complications Trial (DCCT), treating T1DM subjects intensively for a mean of 6.5 years showed that high total cholesterol, high LDL cholesterol, high HbA1c at baseline were associated with the development of CVD during the 17 years of follow-up ([@b81]). In a 7-year study of patients with T2DM, a previous history of MI, low HDL cholesterol, high LDL cholesterol, high TG, and high FPG was associated with a 2-fold increase in the risk of CVD morbidity and mortality ([@b59]). In T2DM, high postprandial TG responses have been associated with MI ([@b10]).

Barriers to effective blood glucose management in diabetes
==========================================================

Before considering the treatment options for CVD risk in diabetes, it should be noted that there are several potential barriers to achieving good glycemic control. Lifestyle issues such as diet, exercise, and weight control are of great importance in managing T2DM, and represent vital opportunities for patients to influence their prognosis with regard to CV complications ([@b84]). Regular exercise, weight loss, and a special diet have been demonstrated to improve insulin sensitivity ([@b70]; [@b111]; [@b54]), which may be beneficial for the prognosis of T2DM, but many patients with T2DM have long-established behavioral patterns and find it very hard to modify their dietary and exercise habits.

The risk of hypoglycemia always exists when blood glucose-lowering therapies are used in patients with diabetes, and this is especially problematic with exogenous insulin therapy. The fear of hypoglycemic events can limit the glycemic control that patients will strive for, and their CV risk may consequently remain higher than necessary ([@b17]).

As noted above, many patients with T2DM are overweight. Diabetes treatments can cause further, unwelcome weight gain ([@b55]). Even when weight gain is not at a clinically significant level, the mere prospect of gaining weight may jeopardize treatment adherence, preventing patients from achieving glycemic targets and indirectly increasing their risk of CVD.

Injection tolerability and the impact of therapy on lifestyle can also be barriers to diabetes treatment. Injecting insulin often becomes a necessity in T2DM, but for some patients, multiple daily injections may be a source of anxiety, discomfort, or pain ([@b35]). Patients may consequently reduce their adherence to therapy, resulting in suboptimal glycemic control.

Some non-modifiable risk factors may also play a role in CVD risk in diabetes. Female gender appears to increase CVD risk in diabetes; women treated with insulin have an especially high mortality risk ([@b56]). Different ethnic groups may have different CV risk factors, such as body weight, lipid profiles, and blood pressure ([@b19]), and a genetic component demonstrated in twin studies may also influence CVD risk in T2DM ([@b73]; [@b87]). Finally, a higher cost of insulin analogs than that of human insulin may also represent a barrier for a number of patients. For others, the improved predictability, tolerability, and flexibility of analogs may make the added expense more acceptable. Better adherence and fewer complications may translate to cost benefits and fewer medical expenses in the long-term ([@b74]). Although cost, treatment satisfaction and other issues may have an important role in the treatment of T2DM they will not be discussed in detail here since the scope of this review is restricted to the clinical aspects of combining insulin and OADs.

Glucose-lowering therapy and CV risk markers
============================================

The mechanisms by which improved glycemic control reduces CV risk are not completely understood, but probably relate to improvement of dyslipidemia, endothelial dysfunction, vasomotor dysfunction, and coagulation abnormalities, all of which are aggravated by hyperglycemia ([@b3]; [@b75]; [@b72]). The recognition that achieving specific glycemic goals can substantially reduce morbidity has made the effective treatment of hyperglycemia a top priority in T2DM.

Initially, such lifestyle changes as diet, exercise and weight loss are utilized in order to reduce the insulin requirements of patients with diabetes. Since T2DM is a progressive disease that causes deterioration over time, addition of medication is the rule, not the exception, if treatment goals are to be met ([@b105]; [@b104]; [@b82]). OADs can be taken as monotherapy or in combination, and are designed either to increase insulin secretion or increase tissue sensitivity ([@b102]). Metformin and thiazolidinediones (TZD) are often used as first-line OADs in an attempt to utilize the insulin still available in patients\' circulation. These OADs can lower blood glucose with a low risk of hypoglycemia, but require the availability of endogenous insulin in order to exert a blood glucose-lowering effect. When OADs do not enable patients to reach glycemic targets, sulphonylureas (SUs) are often added. SUs increase pancreatic insulin secretion as long as sufficient beta-cell function is preserved, but can precipitate hypoglycemia. Their efficacy is comparable to that of the various OADs in improvement of glycemic control, with HbA1c reductions of 1% to 2% usually achieved ([@b4]). With the exception of metformin, however, clear evidence is lacking for a reduction in macrovascular disease specifically associated with OADs ([@b63]).

With the number of oral treatment options currently available, it is important to consider the pathogenesis of T2DM and the risk factors for long-term CV consequences, vascular dysfunction, and inflammation when selecting treatment. The conditions associated with diabetes mean that many patients are prescribed multiple medications, so it is also important to be aware of potential interactions, or at least of the comorbidities remaining to be investigated.

A recent systematic review ([@b8]) concluded that newer, more expensive agents such as TZD, Alpha-glucosidase inhibitors, and meglitinides have effects on glycemic control and CV risk factors (blood pressure, lipids, and body weight) that are similar or superior to those of older agents such as SUs and metformin. An important issue neglected in this review is the additive effect on glycemic control obtained by combining different groups of OADs, since in order for patients to achieve effective improvement and reach their goals for glycemic control, a combination of OAD therapies is often used ([@b100]). For many patients, OAD therapy alone becomes inadequate over time, and insulin is added to the treatment regimen ([@b1]). Indeed, at 9 years after diagnosis, almost 80% of T2DM patients require insulin treatment ([@b104]; [@b113]). Before reviewing the clinical studies using insulin plus OADs, the individual agents currently used in diabetes treatment will be briefly discussed.

Metformin
---------

Metformin suppresses hepatic glucose production and is thought to increase insulin sensitivity ([@b31]). It has been used for decades, and has a long record of safety. Metformin is usually the first OAD used in obese patients because -- unlike other agents, such as SUs -- it does not lead to weight gain ([@b39]). In combination therapy, metformin also appears to limit the weight gain associated with the use of other agents, such as TZDs and SUs ([@b103]; [@b42]). Metformin appears to reduce CV events, although the mechanism is not well understood.

A meta-analysis of 41 randomized controlled trials (RCTs) of metformin involving more than 3000 patients with T2DM reported that metformin effectively lowered HbA1c and modestly reduced total and LDL cholesterol, but had no significant effect on blood pressure, HDL cholesterol, or triglycerides ([@b114]). Indeed, in the ADOPT study, glyburide was associated with a lower risk of cardiovascular events than metformin and rosiglitazone ([@b47]) However, the majority of studies have reported beneficial CV effects with metformin. The UKPDS showed that the intensive use of metformin in obese patients achieved a reduction of 36% in all-cause mortality and 39% in MI ([@b103]). Weight stabilization, improved lipid profile, reduced triglycerides and LDL cholesterol, and increased HDL cholesterol ([@b9]) have also been reported. Metformin has been shown to improve endothelial dysfunction -- a factor closely linked to the development of atherosclerosis ([@b72]). The Hyperinsulinemia the Outcome of its Metabolic Effects (HOME) double-blind trial, which assessed the metabolic and cardiovascular effects of metformin when added to insulin, reported a significant improvement of endothelial function largely unrelated to changes in glycemic control ([@b20]). For these reasons, metformin has been the most commonly used drug in combination with insulin.

There are few limitations for the use of metformin, the most common of which include intolerance to its gastrointestinal side effects and its contraindication in renal or hepatic insufficiency ([@b1]).

Thiazolidinediones
------------------

Insulin sensitizers, TZDs have become very popular in recent years because they exhibit more potent effects on metabolic syndrome parameters associated with insulin resistance than other OADs ([@b31]). Although the precise mechanism of action of TZDs is still under investigation, it appears to be mediated by effects in adipose tissue. TZDs have been shown to cause redistribution of fat with a reduction in visceral adiposity, a marker of insulin resistance ([@b50]).

The TZDs pioglitazone and rosiglitazone have shown similar effects on glycemic control in T2DM, but differential effects on dyslipidemia. A recent meta-analysis of randomized, controlled trials showed differing outcomes on lipid profiles ([@b14]). Pioglitazone had a neutral or beneficial effect on lipids, whereas rosiglitazone appeared to have more complex effects, including an associated increase in both LDL and total cholesterol and a neutral effect on TGs. Both drugs increased levels of HDL cholesterol. Improvements in endothelial dysfunction with associated reduction in microalbuminuria have also been reported ([@b110]) independently of reduction in glycemia and blood pressure ([@b5]). The effects of TZDs on blood pressure have not been consistent, but reduction of blood pressure has been reported ([@b99]). TZDs also appear to decrease plasma C-reactive protein levels in patients with T2DM ([@b34]).

PROACTIVE, a large study in more than 5000 patients with T2DM and known CVD, assessed the effect of pioglitazone on CV mortality and morbidity ([@b25]). In this high-risk study population, an aggressive dose titration of pioglitazone or placebo was used as 'add-on' therapy to current treatment regimes to ensure the best possible glycemic control. There was a nonsignificant reduction in the primary composite endpoint after a mean follow-up of 34 months, and an HbA1c reduction of 0.5% (HR 0.90; p = 0.095); however, despite a significant reduction in the secondary composite endpoint of all-cause mortality, nonfatal MI and stroke were observed (HR 0.84; p = 0.027) ([@b25]).

There are also side effects associated with TZD use, including fluid retention (which can lead to significant weight gain), dilutional anemia and fluid overload. TZDs are contraindicated in patients with heart failure ([@b43]). Importantly, the use of TZDs with insulin has been associated with an increased risk of heart failure ([@b52]). TZDs are consequently contraindicated with insulin use in some countries. In addition, a recent meta-analysis of 42 trials showed that rosiglitazone slightly increased the risk of MI, and might also increase the risk of CV death ([@b83]). This finding has instigated a heated discussion among opinion leaders, but no definitive conclusions on safety have been reached to date.

Insulin secretagogues
---------------------

SUs were a first-line treatment before the introduction of metformin and TZDs; currently, however, they are often placed second after metformin, and sometimes even third after TZDs ([@b1]). Unlike metformin, SUs have not shown any consistent protective role in the development of CVD; moreover, it has been proposed that patients treated with SUs are at an increased risk of macrovascular disease. For example, the UKPDS reported mixed results associated with the use of SUs. Although there was a trend towards a 16% reduction in fatal and non-fatal myocardial infarction ([@b101]), increased mortality was reported in patients treated with SUs plus metformin ([@b103]); however, SU-treated patients were an average of 5 years older, were more hyperglycemic, and were followed for 5 years less than patients who were not treated with SUs.

The main side effects associated with the use of SUs include weight gain (up to several kg) and hypoglycemia, the latter occurring more frequently with the longer-acting SUs (eg, glibenclamide, glyburide). SUs have not been shown to improve blood pressure, and do not appear to have a consistent effect on lipids ([@b4]).

Alpha-glucosidase inhibitors
----------------------------

Alpha-glucosidase inhibitors (AGIs) reduce the rate of digestion of polysaccharides in the proximal small intestine, primarily lowering postprandial glucose levels without causing hypoglycemia. They are less effective than metformin or SUs, reducing HbA1c by 0.5% to 0.8% ([@b108]). Gastrointestinal side effects are common with AGI treatment, and have led to discontinuation in 25% to 45% of participants in clinical trials ([@b108]). Interestingly, a recent meta-analysis of 7 long-term studies of AGI treatment with acarbose in T2DM demonstrated a reduction in CV events ([@b36]); however, this meta-analysis has been criticized for a number of reasons such as publication bias, heterogeneity, detection bias, and confounding factors ([@b107]). A recent Cochrane systematic review and meta-analysis of 41 studies of AGI monotherapy in patients with T2DM of at least 12 weeks did not detect any effect on CV morbidity or mortality ([@b108]). A potential benefit of AGI on CVD therefore still needs to be proven.

Insulin
-------

It has been shown that hyperglycemia contributes to an increased risk of microvascular complications (nephropathy, retinopathy, and neuropathy) ([@b38]), and that lowering glucose levels protects against these complications ([@b24]; [@b103]; [@b105]). Controlling blood glucose with insulin has the potential to be the most effective blood glucose-lowering therapy. Insulin is consistently reported to reduce microvascular complications such as small vessel arterial disease, retinopathy, nephropathy, and neuropathy ([@b24]; [@b105]). In the UKPDS, intensive blood glucose control resulted in a 16% reduction in the risk of MI and a 25% reduction in the risk of microvascular complications ([@b103]); however, there have been conflicting views in the past as to whether insulin actually benefits CVD risk. Some observational studies have reported an association between high insulin levels and an increased risk of CVD ([@b45]; [@b62]), and it has been suggested that hyperinsulinemia predisposes patients to atherosclerosis and its complications ([@b84]).

The RCTs comparing intensive and conventional insulin treatment have more often focused on microvascular rather than macrovascular complications ([@b79]). An exception was the Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study, which assessed the impact of insulin infusion (followed by subcutaneous insulin injections) in patients with T2DM and acute MI ([@b66], [@b65]). Here, a reduction of 28% (p \< 0.05) in relative mortality was reported after 3.4 years in the insulin infusion group compared with a conventional treatment group ([@b66], [@b65]). However, DIGAMI 2 did not support this finding, or the idea that insulin-based treatment lowers the number of nonfatal myocardial reinfarctions and strokes ([@b67]). This disappointing outcome may in part be due to difficulties experienced with recruitment and reaching targets, and the subsequent premature recruitment stop in DIGAMI 2 ([@b67]).

Although some studies report that insulin-treated patients with diabetes have a worse CV prognosis than patients not treated with insulin ([@b64]), this may be seen as intrinsic to the disease process. Patients with more severe diabetes are more likely to be treated with insulin ([@b84]), and insulin users may have had chronically raised blood glucose in the past (in the 'pre-diabetic range'), with CVD symptoms emerging years later -- perhaps around the same time as the need for insulin treatment arose. Atherosclerosis progresses over many years, and the process is likely to begin long before treatment intervention. Insulin users, therefore, are by definition likely to have accrued vascular damage by the time they initiate insulin treatment.

As noted above, most RCTs have not directly investigated the association between insulin use and risk of CV events. However, a number of studies suggest that reduced blood glucose achieved through intensive insulin treatment will ultimately have a beneficial effect on CV risk. For example, in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) study in T1DM, it was shown that intensive treatment has long-term beneficial effects on the risk of CVD ([@b81]). During 17 years of follow-up, intensive treatment reduced the risk of any CVD events by 42%, and the risk of nonfatal MI, stroke, or death from CVD by 57% ([@b81]). The intensive therapy during the DCCT/EDIC study resulted in decreased progression of intima-media thickness 6 years after the end of the trial ([@b80]). The long-term follow-up data suggest that previous intensive treatment of T1DM has an extended benefit well beyond the treatment period.

In the Steno study ([@b28]), T2DM patients with microalbuminuria were treated for a variety of CVD risk factors with multiple interventions, including insulin. Intensified intervention reduced the risk for a combined endpoint of CV mortality, nonfatal MI, nonfatal stroke, coronary intervention, revascularization to legs, and amputation by 50% ([@b29]). This study clearly showed that when an integrated cardiovascular risk factor management program is employed that includes conventional cardiovascular drugs as well as insulin, a positive effect on CV prognosis is likely to be achieved in patients with T2DM.

Insulin with OADs and the treat-to-target concept
=================================================

The UKPDS was one of the first studies to prospectively investigate outcomes in insulin-plus-OAD-treated patients with T2DM, and it showed that the risk of complications can be considerably reduced when 'near-normal' glycemic control is achieved ([@b16]; [@b105]). It demonstrated that early addition of insulin to oral therapy can safely keep HbA1c close to 7.0% in the first 6 years after diagnosis (47% of patients in the SU with insulin group vs. 35% in insulin only group). ([@b113]); however, the UKPDS did not use the modern insulin products currently available.

Many patients remain poorly controlled with OADs, and insulin initiation is often delayed and insulin doses not adjusted aggressively enough. When OAD therapy becomes insufficient, there are several options for insulin initiation. Exogenous insulin administration often aims to mimic the physiological profile of endogenous insulin secretion as closely as possible to match insulin supply to physiological need, but traditional human insulin products do not match this profile precisely. Several types of insulin analogs have been developed by improving the pharmacokinetic profile of human insulin that follows subcutaneous absorption, in order to achieve a better balance between glycemic control and tolerability of treatment. Long-acting insulin analogs simulate the low level, basal insulin secretion seen overnight and between meals, whereas rapid-acting insulin analogs have a fast onset and short duration of action designed to mimic the normal endogenous prandial insulin response, thereby limiting mealtime glucose excursions. Premixed insulin analogs consist of a mixture of a rapid-acting insulin analog and a slower-acting protaminated form of the analog, providing both basal and prandial insulin in one injection.

In recent years, several studies have examined combination treatments with insulin analogs plus OADs using a treat-to-target (TTT) algorithm. Patients usually continued using OADs, while insulin analog was introduced and systematically titrated to a defined glucose target. These studies have shown that with aggressive insulin titration, HbA1c can be reduced to a clinically highly beneficial level. A study by [@b91] was the first trial to use a TTT algorithm in patients poorly controlled with OADs, to which the basal analog insulin glargine was added. Dosage was titrated weekly towards a target FPG ≤ 5.6 mmol/L, and in 6 months, patients achieved impressive reductions in HbA1c, with the majority (\~60%) reaching the target of HbA1c ≤ 7.0%.

[Table 1](#tbl1){ref-type="table"} shows the results of trials comparing long-acting insulin analogs with NPH insulin in insulin-naïve patients with T2DM. Reductions in HbA1c are usually similar between regimens (up to 1.8%), with large proportions of patients achieving targets of HbA1c ≤ 7%. The lack of difference in glycemic control is unsurprising, of course, because of the use of a common glycemic target and titration algorithm; however, use of insulin analogs generally results in a significantly lower risk of hypoglycemia than use of NPH. When basal insulin analogs are initiated, they can achieve clinically meaningful reductions in blood glucose together with a low risk of hypoglycemia ([Figure 2](#fig2){ref-type="fig"}). Thus, a key barrier to insulin titration is lowered, implying that in the everyday clinical setting, patients are more likely to be able to reach guideline glycemic targets without being thwarted by hypoglycemia.

![Mean change in HbA1c (baseline to endpoint) and relative risk for all-day hypoglycemia in comparative trials of basal analogs vs. NPH insulin plus OADs in T2DM.\
**Note:** definitions of hypoglycemia vary by study; the glargine 'relative percentages' have been derived from the study publications and are not comparable to the relative risk data presented for detemir. ^a^p \< 0.05 for between treatment difference in change in HbA1c between baseline and end of trial, or in risk of hypoglycaemia (De Vries et al 2007 \[in press\]). © Reproduced with permission.](vhrm0403-561-02){#fig2}

###### 

Trials of basal insulin analogues in insulin-naïve patients with type 2 diabetes

  Author                                         HbA1c   FPG                                   Hypoglycemia   Weight gain (kg)   Dose                                                                            
  ---------------------- ----------------------- ------- ------------------------------------- -------------- ------------------ ----------------------------------------- ------------------------------------- -----
  [@b41]                 Detemir NPH             8.6     6.8                                   11.1           6.9                RR 0.53[a](#tf1-1){ref-type="table-fn"}   1.2[a](#tf1-1){ref-type="table-fn"}   BD
                                                 8.5     6.6                                   10.8           6.6                                                          2.8                                   ttt
  [@b85]                 Detemir am or pm NPH    9.1     7.5                                   11.5           8.6                RR 0.68                                   1.2                                   OD
                                                 8.9     7.4                                   10.8           7.2                RR 0.47[a](#tf1-1){ref-type="table-fn"}   0.7[b](#tf1-2){ref-type="table-fn"}   ttt
                                                 9.2     7.4                                   11.5           7.8                                                          1.6                                   
  [@b115]                Glargine NPH            9.1     8.34                                                                    \~34%[c](#tf1-3){ref-type="table-fn"}     2.57                                  OD
                                                 8.9     8.24                                                                    \~42%                                     2.34                                  
  Massi-Benedetti 2003   Glargine NPH            9.0     8.5                                   13.0           9.6                35%                                       2.01                                  OD
                                                 8.9     8.5                                   13.1           9.8                41%                                       1.88                                  
  [@b27]                 Glargine am or pm NPH   9.1     7.8[a](#tf1-1){ref-type="table-fn"}   12.1           7.0                74%                                       3.9                                   OD
                                                 9.1     8.1[b](#tf1-2){ref-type="table-fn"}   12.0           6.8                68%                                       3.7                                   
                                                 9.1     8.3                                   12.2           6.9                75%                                       2.9                                   
  [@b91]                 Glargine NPH            8.61    6.96                                  11.0           6.5                13.9%[c](#tf1-3){ref-type="table-fn"}     3.0                                   OD
                                                 8.56    6.97                                  10.8           6.7                17.7 e/pt/yr                              2.8                                   ttt
  [@b26]                 Glargine NPH            9.03    7.65                                  11.2           6.4                52.8%[c](#tf1-3){ref-type="table-fn"}     Not reported                          OD
                                                 9.21    7.78                                  10.8           6.6                62.8%                                                                           ttt

**Notes:** Between-treatment comparison: p \< 0.001;

p \< 0.01;

p \< 0.05.

**Abbreviations:** ttt, treat-to-target study; hypoglycemia RR, relative risk; %, % of patients experiencing hypos; e/pt/y, events per patient year.

Furthermore, when insulin detemir has been used, patients have achieved significant improvements in glycemic control without the excessive weight gain usually associated with insulin use. Two recent studies of insulin detemir added to oral therapy showed HbA1c to decrease by 1.5% to 1.8%, with mean weight gain only half that seen with NPH insulin ([Table 1](#tbl1){ref-type="table"}) ([@b41]; [@b85]). When patients use self-adjusted dosing algorithm, the HbA1c improvements are comparable to those of a physician-driven algorithm, and weight change can be minimal (0.1 kg) ([@b76]). This weight advantage of detemir further appears to relate to body mass index (BMI): patients gain less weight with increasing BMI ([@b40]). These results suggest that with some insulin analogs, it is possible to achieve a good glycemic control with less weight gain than that of comparator insulins. It remains to be established whether better weight control is directly beneficial to CVD risk; however, it may have a beneficial effect on treatment compliance.

Patients who require insulin can also be started on a premixed insulin analog, which allows easy intensification with additional injections of the same insulin. HbA1c reductions can be of a greater magnitude with premixed insulin analogs than with basal analogs ([Table 2](#tbl2){ref-type="table"}), largely because PPG can be better controlled with premixed human insulins than with basal insulin alone. For example, in a 6-month TTT study of insulin initiation, HbA1c was significantly better and a greater proportion of patients reached the target HbA1c \< 7.0% with premixed insulin aspart than with the basal analog insulin glargine (66% vs. 40%, respectively) ([@b88]). A study by [@b30] employed an aggressive titration algorithm to reach the target FPG of 4.5--6.1 mmol/L with premixed insulin aspart. The HbA1c target of \< 7.0% was achieved by 41% of patients with once-daily, by 70% with twice-daily, and by 77% of patients with three times-daily premixed insulin aspart. [Figure 3](#fig3){ref-type="fig"} shows that premixed insulins can achieve greater reductions in HbA1c than basal insulins, but with a slightly higher risk of hypoglycemia. Premixed insulin analogs may therefore represent an effective treatment option in terms of achieving glycemic control, although weight gain and the risk of hypoglycemia may be more of an issue than when basal insulin alone is added to OADs. A recently published study by the 4-T Study Group ([@b44]) compared the use of premixed insulin aspart twice-daily, prandial insulin aspart three-times daily, and basal insulin detemir once daily (twice if required) in patients with type 2 diabetes inadequately controlled with metformin and SUs. After 1 year, HbA1c levels were similar in the premixed insulin group (7.3%) and the pradial group (7.2%), but higher in the basal group (7.6%). However, the respective mean numbers of hypoglycemic events per patient per year were 5.7, 12.0, and 2.3, and weight gains were 4.7 kg, 5.7 kg, and 1.9 kg, suggesting that premixed insulin aspart and prandial insulin aspart reduced HbA1c levels more than basal insulin detemir but were associated with greater risks of hypoglycemia and weight gain ([@b44]).

![Mean change in HbA1c (baseline to endpoint) and relative risk for all-day hypoglycemia in comparative trials of premixed analogs plus OADs in T2DM. Between treatment comparison: ^a^p \< 0.001; ^b^p \< 0.01; ^c^p \< 0.05. ^d^Calculated value.](vhrm0403-561-03){#fig3}

###### 

Trials of premixed insulin analogues in patients with type 2 diabetes

  Author                                                        HbA1c     FPG                                   Hypoglycemia   Weight gain                           Dose                                                                            
  ------------------------------------------ ------------------ --------- ------------------------------------- -------------- ------------------------------------- ----------------------------------------- ------------------------------------- ---------
  Insulin-naïve patients                                                                                                                                                                                                                             
  [@b68]                                     Mix25              8.7       7.4[b](#tf2-2){ref-type="table-fn"}   8.5            7.7[c](#tf2-3){ref-type="table-fn"}   0.68[c](#tf2-3){ref-type="table-fn"} mi   2.3[b](#tf2-2){ref-type="table-fn"}   BID
                                             Glargine           8.7       7.8                                   8.5            6.9                                   0.39 e/pt/30 days                         1.6                                   OD
  [@b53]                                     BIAsp 30           9.5       8.2[e](#tf2-5){ref-type="table-fn"}   13.4           9.2[e](#tf2-5){ref-type="table-fn"}   43%                                       0.7                                   OD
                                             BHI                9.3       8.2[e](#tf2-5){ref-type="table-fn"}   12.6           9.1[e](#tf2-5){ref-type="table-fn"}   32%                                       1.0                                   OD
  [@b88]                                     BIAsp 30           9.7       6.9[b](#tf2-2){ref-type="table-fn"}   14.0           7.1                                   3.4[c](#tf2-3){ref-type="table-fn"}       5.4[b](#tf2-2){ref-type="table-fn"}   BID
                                             Glargine           9.8       7.4                                   13.5           6.5                                   0.7 e/pt/yr                               3.5                                   OD ttt
  [@b47]                                     BIAsp 30           9.21      7.5[a](#tf2-1){ref-type="table-fn"}   11.0           8.6                                   20.3%[c](#tf2-3){ref-type="table-fn"}     0.7                                   BID
                                             Glargine           8.9       7.9                                   11.5           9.1                                   9% mi                                     1.5                                   OD
  Patients previously treated with insulin                                                                                                                                                                                                           
  [@b94]                                     Mix 25                       7.8                                                                                        42%                                                                             BID
                                             BHI 30                       8.1                                                                                        35%                                                                             BID
  [@b94]                                     Mix 25                       7.7                                                  8.9                                   40%                                       none                                  BID
                                             BHI 30                       7.7                                                  9.0                                   37%                                                                             BID
  [@b69]                                     Mix 25             8.5       7.5[a](#tf2-1){ref-type="table-fn"}   8.4            7.9[b](#tf2-2){ref-type="table-fn"}   0.61                                      0.8[a](#tf2-1){ref-type="table-fn"}   BID
                                             Glargine           8.5       8.1                                   8.4            7.4                                   0.44 e/pt/30 days                         0.1                                   OD
  [@b7][d](#tf2-4){ref-type="table-fn"}      BIAsp 30           8.4/8.1   8.1                                                  8.9                                   20mj/362mi                                                                      BID
                                             BHI 30             8.4/8.2   8.2                                                  8.2                                   42mj/361mi                                                                      BID
  [@b61]                                     BIAsp 30           8.4       7.2[b](#tf2-2){ref-type="table-fn"}   11             8.1                                   28%                                       2.2                                   BID
                                             Detemir + aspart   8.2       7.0                                   11.2           8.2                                   31% mi                                    2.2                                   OD
  [@b30]                                     BIAsp 30           8.6       7.2                                   9.2            6.4                                   15.4                                      \~0.5                                 OD,
                                                                                                                                                                     22.4                                                                            BID,
                                                                                                                                                                     12.0 e/pt/yr                                                                    TID ttt

**Notes:** Between-treatment comparison: p \< 0.001;

p \< 0.01;

p \< 0.05;

Includes type 1 and 2 diabetes patients;

Calculated value.

**Abbreviations:** ttt, treat-to-target study; hypoglycemia %, % of patients experiencing hypos; e/pt/y, events per patient year; mj, major; mi, minor.

There is currently no consensus as to which option represents the best way to initiate and intensify insulin treatment. Patients are often started on a once-daily basal insulin analog at bedtime, which improves FPG with a relatively low risk of nocturnal hypoglycemia. Using this strategy, PPG excursions may be controlled by a combination of OADs and the recovered beta-cell secretory capacity that basal insulin supplementation may afford. There does seem to be a limit to the HbA1c reduction that can be achieved when basal insulin alone is added to OADs, as evidenced by the observation that studies involving cohorts with higher baseline levels of HbA1c tend to achieve mean absolute HbA1c levels at endpoint that, while improved, remain above target ([@b23]). There is also evidence that the effect of a once-daily basal insulin is more likely to wane across 24 hours when baseline control is poorer, and that splitting the dose will merely escalate the dose without a corresponding gain in control ([@b23]). These observations likely reflect in part an increasing failure to limit postprandial glycemic control with progressing T2DM.

Furthermore, as HbA1c decreases, so PPG contributes an increasing proportion of the residual hyperglycemia ([@b77]). It follows that in order to achieve HbA1c treatment goals, PPG control must be targeted as well, particularly in more advanced disease. When OADs no longer adequately control PPG excursions, prandial insulin can be added at mealtimes, one meal at a time, to a simple basal insulin regimen. Alternatively, premixed insulin formulations can be used for insulin initiation and intensification of treatment, with the advantage of fewer daily injections but more limited flexibility. Using this approach, patients can use the same insulin in the same device, just increasing the number of daily injections ([@b30]). Ongoing studies will likely discern patient preferences and the optimal treatment strategies for defined patient types.

Conclusions
===========

It is well established that patients with diabetes are at a high risk of CVD. Blood glucose control appears to be an important factor in reducing the CVD risk and potential CV mortality in diabetes patients. Most studies examining insulin plus OADs have focused on insulin, with OADs usually grouped together -- although most trials have used metformin as either the only OAD or in combination with other OADs (eg, [@b91]; [@b40]; [@b85]). The combination of insulin plus OADs has been associated with improvements in CV risk markers in early outcome studies, but studies examining the interactions of various antidiabetic treatments would also be helpful.

The TTT studies have shown that insulin analogs plus OAD can help patients to achieve excellent glycemic control. Adding a basal insulin analog to OAD therapy improves HbA1c by 1.5% to 1.8%, with a low risk of hypoglycemic events. Premixed insulin analogs have shown greater HbA1c reductions, but considerable weight gain; however, the long-acting insulin analog detemir appears to limit the weight gain usually present with insulin use ([@b40]; [@b85]). This effect may help improve adherence to treatment.

There are different views as to which approach is the best option for initiation or intensification of insulin, when the need arises. With a basal insulin analog injection as a start, rapid-acting insulin can be added at mealtimes. On the other hand, premixed insulin analogs contain both basal and prandial insulin in one injection. The clinician and patient must decide which of these options they find more acceptable. Observational studies have also shown that patients can easily manage self-monitoring and self-titration of insulin analogs ([@b18]; [@b76]). Insulin analogs appear to be a better option than conventional insulins for achieving the balance between glycemic control and risk of hypoglycemia. Data concerning the impact of different insulin plus OAD regimens on CVD markers other than hyperglycemia are currently lacking, yet have the potential to guide treatment choices.

The role of OAD and of insulin-OAD combination regimens may change in the future as a result of the development of newer therapies. For example, glucagon-like peptide 1 (GLP-1) analogs, GLP-1 agonists and dipeptidyl peptidase IV (DPP-4) inhibitors represent very promising treatment options for patients with T2DM. GLP-1 secretion may be impaired in T2DM, and GLP-1 analogs and agonists and DPP-4 inhibitors that increase endogenous GLP-1 production have the advantage that their effect on insulin secretion depends on plasma glucose concentration. The first studies of GLP-1 analogs show encouraging improvements in glycemic control without the risk of hypoglycemia and with a dose-dependent reduction in weight, a combination promising a potential CVD benefit ([@b22]; [@b109]). It should be noted that despite its HbA1c- lowering effect, the DPP-4 inhibitor sitagliptin increases the risk of hypoglycemia when combined with SUs ([@b42]). Although it remains to be determined whether these agents are likely to be used with insulin, an agent controlling glucose levels while decreasing weight gives rise to hope for beneficial treatment possibilities. Large, long-term comparative studies of major clinical endpoints, such as CVD, MI, and CV mortality, are needed to determine the comparative effects of OADs

In summary, it seems sensible to establish glycemic control in patients with T2DM by utilizing such lifestyle changes as diet intervention and exercise; however, current studies have shown that excellent glycemic control will ultimately require insulin treatment, at least in the more advanced stages of T2DM, and that this can be achieved with insulin plus OAD with a TTT approach. Patients and clinicians need to gain more confidence in initiating and titrating insulin, as this approach can lead to a better prognosis in terms of diabetes complications, including a reduced risk of CVD. A comprehensive approach for preventing and/or ameliorating the CV complications of diabetes would also require the use of lipid-lowering medication, control of blood pressure, and anticoagulation medication.
